Mark R Player

Process technologies for purity enhancement of large discovery libraries.

Richard S Pottorf, Mark R Player, 2004, Current opinion in drug discovery & development.

Crystal Structure of the Tyrosine Kinase Domain of Colony-stimulating Factor-1 Receptor (cFMS) in Complex with Two Inhibitors*

Mark R Player, J. Spurlino, R. Patch, 2006, Journal of Biological Chemistry.

7-fluoroindazoles as potent and selective inhibitors of factor Xa.

Mark R Player, D. Parks, Yu-Kai Lee, 2008, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists.

Maxwell D Cummings, Mark R Player, D. Parks, 2005, Bioorganic & medicinal chemistry letters.

Discovery and SAR of novel Naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK).

Renee L DesJarlais, Mark R Player, R. DesJarlais, 2003, Bioorganic & medicinal chemistry letters.

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.

Mark R Player, Sharmila Patel, M. Player, 2008, Expert opinion on investigational drugs.

Structure-based optimization of a potent class of arylamide FMS inhibitors.

Jinsheng Chen, Mark R Player, B. Tomczuk, 2008, Bioorganic & medicinal chemistry letters.

2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors.

Mark R Player, B. Tomczuk, J. Spurlino, 2007, Bioorganic & medicinal chemistry letters.